Get the Stockscreener App
8.471
2.46%
-0.214
Passage Bio Inc stock is traded at $8.471, with a volume of 55,115.
It is down -2.46% in the last 24 hours and up +19.99% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$8.685
Open:
$8.9709
24h Volume:
55,115
Relative Volume:
0.49
Market Cap:
$26.93M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-7.2402
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
+6.55%
1M Performance:
+19.99%
6M Performance:
+2,241%
1Y Performance:
+1,336%
1-Day Range:
$8.00
$9.00
1-Week Range:
$7.84
$9.00
52-Week Range:
$0.257
$9.00
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
8.471 | 27.61M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Why Passage Bio Inc. stock could rally in 2025July 2025 Breakouts & Safe Capital Growth Tips - newser.com
What’s next for Passage Bio Inc. stock price2025 Stock Rankings & Safe Entry Trade Reports - newser.com
What the charts say about Passage Bio Inc. todayWeekly Risk Report & High Yield Equity Trading Tips - newser.com
How to build a custom watchlist for Passage Bio Inc.July 2025 Drop Watch & Free Weekly Watchlist of Top Performers - newser.com
Full technical analysis of Passage Bio Inc. stockWeekly Profit Analysis & Real-Time Chart Pattern Alerts - newser.com
Key resistance and support levels for Passage Bio Inc.July 2025 Sentiment & Detailed Earnings Play Strategies - newser.com
What analysts say about Passage Bio Inc stockTechnical Pattern Recognition & Consistently Superior Profits - earlytimes.in
Passage Bio Inc. stock daily chart insightsTake Profit & Weekly Watchlist of Top Performers - newser.com
How buybacks impact Passage Bio Inc. stock valueTrade Risk Report & AI Driven Stock Reports - newser.com
Passage Bio Inc Stock Analysis and ForecastTrend Following Strategies & Rapid Portfolio Expansion - earlytimes.in
Is it too late to sell Passage Bio Inc.Bull Run & Weekly High Momentum Picks - newser.com
Is Passage Bio Inc. stock poised for growthWeekly Risk Report & Safe Capital Preservation Plans - newser.com
Is Passage Bio Inc. reversing from oversold territory2025 Pullback Review & High Accuracy Trade Signal Alerts - newser.com
Passage Bio (NASDAQ:PASG) Trading Up 1.8% – Time to Buy? - Defense World
Is Passage Bio Inc a good long term investmentMACD Histogram Signals & Investment Risk Management Tips - earlytimes.in
How institutional ownership impacts Passage Bio Inc. stockWeekly Trend Report & Safe Swing Trade Setups - newser.com
GM1 Gangliosidosis Market: Epidemiology, Therapies, Companies – DelveInsight | Featuring Passage Bio Inc., Gain Therapeutics, Sio Gene Therapies - The Globe and Mail
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Retail Surge: Can Passage Bio Inc ride the EV waveWeekly Trading Summary & High Accuracy Trade Signal Alerts - خودرو بانک
Can machine learning forecast Passage Bio Inc. recoveryJuly 2025 Final Week & Free Expert Approved Momentum Trade Ideas - newser.com
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Passage Bio Inc Stock (PASG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Sep 15 '25 |
Buy |
6.99 |
11,900 |
83,175 |
623,704 |
| Lynx1 Capital Management LP | 10% Owner |
Sep 11 '25 |
Buy |
6.96 |
325 |
2,261 |
592,021 |
| Lynx1 Capital Management LP | 10% Owner |
Jul 24 '25 |
Buy |
5.71 |
66,423 |
379,455 |
591,696 |
| Lynx1 Capital Management LP | 10% Owner |
Jul 23 '25 |
Buy |
5.74 |
49,302 |
283,033 |
525,273 |
| Lynx1 Capital Management LP | 10% Owner |
Jul 22 '25 |
Buy |
5.44 |
13,123 |
71,338 |
475,971 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):